Home
> ... > Medicine, Hematology Oncology Division
> Leo I Gordon

Edit your profile

Leo I Gordon
Feinberg School of Medicine, Feinberg Clinical, Medicine, Hematology Oncology Division

Home
Expert Overview
Profile
Publications
Grants
Patents
Similar Experts
Journals
Trends
Institutional Network
Coauthor Network
Research Network
Curriculum Vitae

Leo I Gordon

Schools & Departments
Feinberg School of Medicine

Feinberg Clinical

Medicine, Hematology Oncology Division

Current Appointments:
Professor; Medicine, Hematology Oncology Division; Feinberg School of Medicine

Research Interest Keywords

Apoptosis, Bone Marrow Transplantation, Cancer Biology, Cancer: Blood (leukemia, lymphomas), Hodgkin's Disease, Leukemia, Lymphomas, Monoclonal Antibodies, Non-Hodgkin's Lymphoma, Stem Cells, Transplantation

Office phone

312/695-4546

Email

Research Statement: The overarching goal of my involvement in translational research is to improve the outcome of patients with lymphoma. With scientists in the US and abroad, we are currently investigating novel signaling pathways in lymphoma, using cell lines and animal model systems. More specifically, our research focuses on the biology of reactive oxygen species signaling pathways in lymphoma. Active investigations include: 1) the biology of the lactone diterpenoids in lymphoma; 2) the development of all trans retinoic acid (ATRA) and curcumin loaded nanodisks as a drug delivery vehicle in mantle cell lymphoma (MCL), in collaboration with investigators from the Children’s Hospital Research Institute (CHORI) in Oakland, CA 3) The characterization of cholesterol efflux pumps as a target in lymphoma, in collaboration with Dr Colby Shad Thaxton from the Department of Urology and the Northwestern University Center of Cancer Nanotechnology excellence; 4) the study of hypoxia inducible factor (HIF) in lymphoma, in collaboration with Dr. Paul Schumacker. Clinical research interests include the study of novel immune stimulatory strategies following stem cell transplant in lymphoma with collaborators in Israel, Europe and the US, new approaches to the use of radioimmunotherapy (RIT) in lymphoma, and new treatment paradigms based on the basic investigations described above Clinical research studies are carried out through the Northwestern University Lymphoma Program and through national co-operative groups such as the Eastern Cooperative Oncology Group (ECOG), SPORE programs in lymphoma and through the NCI Phase II Consortium in collaboration with investigators at the University of Chicago.

Profile

Trends

Explore the Research Trends

Research Network

Explore the Expert Network

Publications

1.
2013

Andrew M. Evens; Fangxin Hong; Leo I. Gordon; Richard I. Fisher; Nancy L. Bartlett; Joseph M. Connors; Randy D. Gascoyne; Henry Wagner; Mary Gospodarowicz; Bruce D. Cheson; et al.

The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: A comprehensive analysis from the North American intergroup trial E2496
British Journal of Haematology. 2013;161(1):76-86.
2.
2013

Richard W. Ahn; Susan L. Barrett; Meera R. Raja; Jennifer K. Jozefik; Lidia Spaho; Haimei Chen; Marcel B. Bally; Andrew P. Mazar; Michael J. Avram; Jane N. Winter; et al.

Nano-Encapsulation of Arsenic Trioxide Enhances Efficacy against Murine Lymphoma Model while Minimizing Its Impact on Ovarian Reserve In Vitro and In Vivo
PLoS ONE. 2013;8(3).
3.
2013

Rupali Roy; Andrew M. Evens; David Patton; Lillia Gallot; Annette Larson; Alfred Rademaker; Jeffrey Cilley; Stewart Spies; Daina Variakojis; Leo I. Gordon; et al.

Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: A phase i trial of combined induction therapy and bortezomib consolidation
Leukemia and Lymphoma. 2013;54(3):497-502.

Similar Experts

Journals

Publications
Blood

23
Bone Marrow Transplantation

23
Journal of Clinical Oncology

22
Leukemia and Lymphoma

15
JNCCN Journal of the National Comprehensive Cancer Network

12

Grants

1.

Leo Gordon; Hugh Anderson; Brandon Miller

Prot# SGN35-005: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of SGN-35 (brentuximab vedotin) and Best Supportive Care (BSC) versus Placebo and BSC in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma (HL) Following Autologous Stem Cell Transplant (ASCT)

12/15/2012 - 12/15/2015
Document ID: SGN35-005
Sponsor: Seattle Genetics, Inc.
2.

Leo Gordon

MAP Kinase Signaling in Lymphoma: A Novel Therapeutic Paradigm

8/10/2012 - 5/31/2013
Document ID: 6143764/RFS2013035//1R01CA164311-01
Sponsor: University of Massachusetts Medical School
3.

Leo Gordon

Prot# GAO4915g: A Phase II, Open-Label, Multicenter Study of Efficacy, Safety, And Biomarkers in Patients With Previously Untreated Advanced Diffuse Large B-cell Lymphoma Treated with GA101 (RO5072759) in Combination With Chop Chemotherapy

12/15/2011 - 12/15/2014
Document ID: GAO4915g
Sponsor: Genentech, Inc.

Institutional Network

Internal Organizations

Shared Pub.
Pathology

33
Preventive Medicine

17
Radiology

14
Lurie Cancer Center

5
Medicine, Immunotherapy for Autoimmune Disease Division

3
Microbiology-Immunology

3

External Organizations

Shared Pub.
Mayo Clinic

23
University of Chicago

21
Fox Chase Cancer Center

20
Roswell Park Cancer Institute

18
Biogen IDEC

12
Memorial Sloan-Kettering Cancer Center

12

Coauthor Network

Internal Coauthors

Shared Pub.
Jane Norma Winter

53
Jayesh Mehta

25
Seema Singhal

23
Stephanie Williams

18
Steven T Rosen

16
Daina Variakojis

16

External Coauthors

Shared Pub.
Myron S Czuczman

20
Thomas E Witzig

19
Christos Emmanouilides

15
Andrew M Evens

15
Gregory A Wiseman

15
Christine A White

13

© 2013 Elsevier B.V All rights reserved. SciVal ® is a registered trademark of Elsevier Properties SA | About SciVal Experts | Terms and conditions | Privacy statement | Contact

This project is supported in part by NIH NCRR Grant 3UL1RR025741-04S3 awarded to the NUCATS Institute at Northwestern University.

Cookies are set by this site. To decline them or learn more, visit our Cookies page.